SRT 1720 Hydrochloride 是选择性的SIRT1激活剂，EC50为 0.10 μM，对 SIRT2 和 SIRT3 的作用较弱。

SRT 1720 Hydrochloride is a selective activator of SIRT1 with an EC 50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 [1].

SRT 1720 effectively decreases the acetylation of p53 in cells even in the absence of SIRT1, and this is attributed to inhibition of histone acetyltransferase p300 [2].

SRT 1720 (10, 30, 100 mg/kg, p.o.) treatment significantly reduces fasting blood glucose to near normal levels in Lep ob/ob mice [1]. SRT 1720 has ability to protect against the negative effects of diet-induced obesity in mice, and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1α and FOXO1 [2]. SRT 1720 (50-100 mg/kg, p.o.), during emphysema development attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice [3].

2060259-60-9

C25H24ClN7OS

506.02

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years